Company / Return on Assets (ROA)
Matinas BioPharma Holdings, Inc. Return on Assets (ROA) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-191.8%
FY2024
5-year range
-191.8% / -31.6%
FY2020-FY2024
Trend
-129.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has declined for 4 consecutive years, from -31.6% in FY2020 to -191.8% in FY2024.
Based on SEC 10-K filings.
-191.8% in FY2024 with a 5-year CAGR of -156.8%.
Declined from -51.9% to -191.8% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -153.9pp
- 5-Year Change
- -156.8pp
- 10-Year Change
- -
Key checks
Key Insights
- Matinas BioPharma Holdings, Inc.'s return on assets (roa) has declined for 4 consecutive years.
- In FY2024, return on assets (roa) decreased 129.4% year-over-year.
- Peak return on assets (roa) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -191.8% | -129.4% |
| FY2023 | -83.6% | -61.0% |
| FY2022 | -51.9% | -36.8% |
| FY2021 | -38.0% | -20.0% |
| FY2020 | -31.6% | +9.6% |
| FY2019 | -35.0% | +54.9% |
| FY2018 | -77.6% | -22.6% |
| FY2017 | -63.3% | +18.2% |
| FY2016 | -77.4% | +28.8% |
| FY2015 | -108.7% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026